Literature DB >> 11924572

Human osteoblasts' proliferative responses to strain and 17beta-estradiol are mediated by the estrogen receptor and the receptor for insulin-like growth factor I.

Ming Zhao Cheng1, Simon C F Rawlinson, Andrew A Pitsillides, Gul Zaman, Subburaman Mohan, David J Baylink, Lance E Lanyon.   

Abstract

The mechanism by which mechanical strain and estrogen stimulate bone cell proliferation was investigated using monolayer cultures of human osteoblastic TE85 cells and female human primary (first-passage) osteoblasts (fHOBs). Both cell types showed small but statistically significant dose-dependent increases in [3H]thymidine incorporation in response to 17beta-estradiol and to a single 10-minute period of uniaxial cyclic strain (1 Hz). In both cell types, the peak response to 17beta-estradiol occurred at 10(-8) - 10(-7) M and the peak response to strain occurred at 3500 microstrain ((mu)epsilon). Both strain-related and 17beta-estradiol-related increases in [3H]thymidine incorporation were abolished by the estrogen receptor (ER) modulator ICI 182,780 (10-8 M). Tamoxifen (10(-9) - 10(-8) M) increased [3H]thymidine incorporation in both cell types but had no effect on their response to strain. In TE85 cells, tamoxifen reduced the increase in [3H]thymidine incorporation associated with 17beta-estradiol to that of tamoxifen alone but had no such effect in fHOBs. In TE85 cells, strain increased medium concentrations of insulin-like growth factor (IGF) II but not IGF-I, whereas 17beta-estradiol increased medium concentrations of IGF-I but not IGF-II. Neutralizing monoclonal antibody (MNAb) to IGF-I (3 microg/ml) blocked the effects of 17beta-estradiol and exogenous truncated IGF-I (tIGF-I; 50 ng/ml) but not those of strain or tIGF-II (50 ng/ml). Neutralizing antibody to IGF-II (3 microg/ml) blocked the effects of strain and tIGF-II but not those of 17beta-estradiol or tIGF-I. MAb aIR-3 (100 ng/ml) to the IGF-I receptor blocked the effects on [3H]thymidine incorporation of strain, tIGF-II, 17beta-estradiol, and tIGF-I. HOBs and TE85 cells, act similarly to rat primary osteoblasts and ROS 17/2.8 cells in their dose-related proliferative responses to strain and 17beta-estradiol, both of which can be blocked by the ER modulator ICI 182,780. In TE85 cells (as in rat primaries and ROS 17/2.8 cells), the response to 17beta-estradiol is mediated by IGF-I, and the response to strain is mediated by IGF-II. Human cells differ from rat cells in that tamoxifen does not block their response to strain and reduces the response to 17beta-estradiol in TE85s but not primaries. In both human cell types (unlike rat cells) the effects of strain and IGF-II as well as estradiol and IGF-I can be blocked at the IGF-I receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11924572     DOI: 10.1359/jbmr.2002.17.4.593

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  22 in total

Review 1.  Effects of estrogen replacement on metabolic factors that influence physical performance in female hypogonadism.

Authors:  W M Kohrt; R E Van Pelt; W S Gozansky
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 2.  Mechanotransduction in human bone: in vitro cellular physiology that underpins bone changes with exercise.

Authors:  Alexander Scott; Karim M Khan; Vincent Duronio; David A Hart
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

3.  Estrogen receptors' roles in the control of mechanically adaptive bone (re)modeling.

Authors:  Gabriel L Galea; Joanna S Price; Lance E Lanyon
Journal:  Bonekey Rep       Date:  2013-09-04

4.  Pyk2 deficiency potentiates osteoblast differentiation and mineralizing activity in response to estrogen or raloxifene.

Authors:  Sumana Posritong; Jung Min Hong; Pierre P Eleniste; Patrick W McIntyre; Jennifer L Wu; Evan R Himes; Vruti Patel; Melissa A Kacena; Angela Bruzzaniti
Journal:  Mol Cell Endocrinol       Date:  2018-02-08       Impact factor: 4.102

Review 5.  Men, bone and estrogen: unresolved issues.

Authors:  E S Orwoll
Journal:  Osteoporos Int       Date:  2003-03-04       Impact factor: 4.507

Review 6.  Sex hormones and their receptors in bone homeostasis: insights from genetically modified mouse models.

Authors:  L Vico; J-M Vanacker
Journal:  Osteoporos Int       Date:  2009-06-03       Impact factor: 4.507

7.  Estrogen receptor alpha CA dinucleotide repeat polymorphism is associated with rate of bone loss in perimenopausal women and bone mineral density and risk of osteoporotic fractures in postmenopausal women.

Authors:  B M H Lai; C L Cheung; K D K Luk; A W C Kung
Journal:  Osteoporos Int       Date:  2007-09-26       Impact factor: 4.507

Review 8.  Skeletal effects of growth hormone and insulin-like growth factor-I therapy.

Authors:  Richard C Lindsey; Subburaman Mohan
Journal:  Mol Cell Endocrinol       Date:  2015-09-25       Impact factor: 4.102

9.  Mechano-transduction in osteoblastic cells involves strain-regulated estrogen receptor alpha-mediated control of insulin-like growth factor (IGF) I receptor sensitivity to Ambient IGF, leading to phosphatidylinositol 3-kinase/AKT-dependent Wnt/LRP5 receptor-independent activation of beta-catenin signaling.

Authors:  Andrew Sunters; Victoria J Armstrong; Gul Zaman; Robert M Kypta; Yoshiaki Kawano; Lance E Lanyon; Joanna S Price
Journal:  J Biol Chem       Date:  2009-12-30       Impact factor: 5.157

10.  Loading-related regulation of gene expression in bone in the contexts of estrogen deficiency, lack of estrogen receptor alpha and disuse.

Authors:  Gul Zaman; Leanne K Saxon; Andrew Sunters; Helen Hilton; Peter Underhill; Debbie Williams; Joanna S Price; Lance E Lanyon
Journal:  Bone       Date:  2009-10-24       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.